Atagabalin
Atagabalin is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α2δ calcium channels. It was under development as a treatment for insomnia, but was discontinued following unsatisfactory trial results. The drug reached phase 2 clinical trials for this indication prior to the discontinuation of its development.